Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SY‑079

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Dana-Farber Cancer Institute, Syros

Drug class:

CDK7 inhibitor

Related drugs:

CDK7 overexpression	Cholangiocarcinoma	CDK7 overexpression	Cholangiocarcinoma	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D
AR expression	Prostate Cancer	AR expression	Prostate Cancer	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D
CD133 positive	Glioblastoma	CD133 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
CD44 positive	Glioblastoma	CD44 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D